Vizz
(Aceclidine)Phase 1Small molecule
This eye drop medication is used to treat presbyopia, which is the age-related difficulty in focusing on close objects. It works by activating the eye muscle responsible for adjusting focus, helping to improve your ability to see nearby objects clearly.[1] Vizz is currently being investigated across 1 indication[3], with its most advanced program in Phase 1.[1]
Vizz is one of 14 small molecule programs targeting Presbyopia. It is currently in Phase 1.
1
Indications
8
Total Trials
0
Active Trials
13
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
6
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
28 competitors in Presbyopia
#DrugCompanyPhaseTrials
1Bromday
BBausch Health Americas, Inc.
Approved
Alphagan
AbbViePhase 3
Alphagan
NovartisPhase 3
Isopto Carpine
AAdvanz Pharma
Phase 3
Pilocarpine Hcl
AbbViePhase 3
Miostat
FFalcon
Phase 2
Restasis
TTaiwan Bio Therapeutics Inc.
Phase 1
AGN-199201
AbbViePhase 2
AGN-190584
AbbViePhase 2
BAY 2701439
BayerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Presbyopia8 trials
Show 5 more trials
Regulatory
FDA Approval Timeline[4]
Jul 31, 2025
VIZZ
NDA NDA218585
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Aceclidine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]FDA Orange Book — Patent and exclusivity data for Vizz. U.S. Food & Drug Administration.
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- LLENZ Therapeutics, Inc